Other anti-HER2 ADCs, such as zanidatamab zovodotin (ZW49), a bispecific antibody directed against two non-overlapping HER2 epitopes linked to an anti-microtubule agent, showed an overall response rate (ORR) of 28% and disease control rate (DCR) of 72% across numerous cancer types (NSCLC rate not specified) in a phase 1 trial with a good safety profile, meriting future investigation [41]. Here, ERBB2 is linked to cancer.